Perioperative or neo/adjuvant chemoimmunotherapy versus chemotherapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis
Abstract Introduction Lung cancer, particularly non-small cell lung cancer (NSCLC), is a leading cause of cancer-related deaths globally. Despite surgery being the main treatment for resectable NSCLC, many patients experience postoperative recurrence. Neoadjuvant chemotherapy may shrink tumors and i...
Saved in:
Main Authors: | Qiong Zhang, Jia Duan, Yuanmei Zhang, Lei Yang, Duo Li |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Systematic Reviews |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13643-025-02767-6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief Report
by: Yichen Dong, MD, et al.
Published: (2025-01-01) -
Chemoimmunotherapy as induction treatment in concurrent chemoradiotherapy for patients with nasopharyngeal carcinoma stage IVa
by: Kun-Peng Wu, et al.
Published: (2025-12-01) -
Efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB non-small cell lung cancer (periSCOPE): an open-label, single-arm, phase II trialResearch in context
by: Xiangyang Yu, et al.
Published: (2025-01-01) -
Neoadjuvant chemoimmunotherapy for locally advanced squamous cell carcinoma of the head and neck: Systematic review and meta-analysis
by: Xiayi Zhu, et al.
Published: (2025-02-01) -
Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I‐II pancreatic cancer
by: Sung Jun Ma, et al.
Published: (2019-03-01)